@article{801e830804704f0da141026d2c909157,
title = "The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram",
abstract = "Background: Static and dynamic functional connectivity are being increasingly used to measure the effects of disease and a range of different interventions on brain networks. While preliminary evidence suggests that static connectivity can be modulated by chronic antidepressants administration in healthy individuals and in major depression, much less is known about the acute effects of antidepressants especially on dynamic functional connectivity changes. Here we examine acute effects of antidepressants on dynamic functional connectivity within the default mode network. The default mode network is a well described network with many functions in which the role of serotonin is not clear. Methods: In this work we measured acute pharmacological effects of an infusion of the selective serotonin reuptake inhibitor (SSRI) citalopram (10 mg) in a sample of thirteen healthy volunteers randomised to receive on two occasions the active compound or placebo in a cross over dosing. Results: Acute citalopram administration relative to placebo increased static connectivity between the medial prefrontal cortex and right dorsolateral prefrontal cortex and posterior cingulate cortex. The SSRI also induced a reduction in variability of connectivity with the medial prefrontal cortex in the precuneus and posterior cingulate cortex. Discussion: The measured changes are compatible with modified serotonin cortical availability.",
keywords = "Citalopram, Functional MRI, MRI, SSRI, Serotonin",
author = "D. Arnone and T. Wise and C. Walker and Cowen, {P. J.} and O. Howes and S. Selvaraj",
note = "Funding Information: This study was supported by Academy of Medical Sciences UK grant to Dr. Selvaraj (no. AMS- SGCL6 ) and by Medical Research Council -UK (no. MC-A656-5QD30 ), Brain and Behavior Research Foundation , and Wellcome Trust (no. 094849/Z/10/Z ) grants to Dr. Howes and the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London . The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Dr. Arnone was supported by the Academy of Medical Sciennces , UK (grant no. AMS-SGCL8 ). The authors are grateful to all the participants and the staff at the Hammersmith Imanet (Andrew Blyth, Hope McDevitt, Andreanna Williams, Safiye Osman and Noora Ali) and MRI unit Hammersmith Hospital (Robert Steiner) for the technical expertise and support they provided. Dr. Arnone and Dr. Wise would like to thank Professor AJ Cleare for his support. Funding Information: All procedures were approved by the National Research Ethics Service, West London Committee. Dr. Arnone has received travel grants from Jansenn-Cilag and Servier. Dr. Wise was supported by a PhD studentship from the National Institute of Health Research. Dr. Cowen has been a member of advisory boards of Servier and Lundbeck and has been a paid lecturer for Servier and Lundbeck. Dr. Howes has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organised by Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. Neither Dr. Howes or his family have been employed by or have holdings/a financial stake in any biomedical company. Intravenous citalopram was kindly provided by Lundbeck, UK. There were no other disclosures or conflicts of interest reported by the authors. Publisher Copyright: {\textcopyright} 2018",
year = "2018",
month = jun,
day = "8",
doi = "10.1016/j.pnpbp.2018.01.021",
language = "English (US)",
volume = "84",
pages = "152--159",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier",
number = "Pt A",
}